AxoGen (NASDAQ:AXGN) Director Kathy Johnson Weiler Sells 14,150 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Kathy Johnson Weiler sold 14,150 shares of AxoGen stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AxoGen Stock Up 0.5%

AxoGen stock opened at $48.48 on Wednesday. The company’s 50-day moving average price is $43.01 and its two-hundred day moving average price is $38.14. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. The stock has a market cap of $2.61 billion, a P/E ratio of -71.29 and a beta of 1.11. AxoGen, Inc. has a twelve month low of $13.64 and a twelve month high of $49.12.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The company had revenue of $69.73 million during the quarter, compared to analysts’ expectations of $67.10 million. As a group, analysts expect that AxoGen, Inc. will post -0.45 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on AXGN. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a report on Sunday, July 26th. Wells Fargo & Company lifted their target price on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of AxoGen in a research report on Friday, May 29th. Citizens Jmp increased their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Thursday, July 30th. Finally, Truist Financial set a $55.00 target price on AxoGen in a report on Thursday, July 30th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of AxoGen in the second quarter worth approximately $204,123,000. Balyasny Asset Management L.P. lifted its stake in shares of AxoGen by 183.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock valued at $20,953,000 after purchasing an additional 1,250,968 shares during the period. Wasatch Advisors LP increased its holdings in AxoGen by 101.1% in the first quarter. Wasatch Advisors LP now owns 1,857,350 shares of the medical equipment provider’s stock worth $61,534,000 after purchasing an additional 933,778 shares in the last quarter. Millennium Management LLC lifted its stake in AxoGen by 2,255.8% in the fourth quarter. Millennium Management LLC now owns 971,358 shares of the medical equipment provider’s stock valued at $31,793,000 after buying an additional 930,126 shares during the period. Finally, Next Century Growth Investors LLC acquired a new position in AxoGen in the fourth quarter valued at approximately $26,180,000. 80.29% of the stock is owned by institutional investors and hedge funds.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.